Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.4% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
3(100.0%)
3Total
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07760961Phase 2Not Yet Recruiting

Effect of Mizagliflozin on Hypoglycemia in Patients With Post-Bariatric Hypoglycemia

Role: lead

NCT05721729Phase 2Completed

Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions

Role: lead

NCT05541939Phase 2Completed

Effect of Mizagliflozin on Postprandial Glucose and Insulin in Post-Bariatric Hypoglycemia Subjects

Role: lead

All 3 trials loaded